Paxlovid (Ritonavir an HIV Drug), Pfizer’s COVID-19 Pill, Prevents 9 Out of 10 Hospital Admissions

Paxlovid the trade name of a new drug by Pfizer that is based on ritonavir an already available AIDS drug could be a game-changer in the fight against SARS-CoV-2. The company claims that this repurposed molecule already used to treat HIV infections is also 89% effective in preventing the risk of hospitalization and death following SARS-CoV-2 infection. Pfizer plans to submit an application to the FDA as soon as possible.Pfizer Logo

Read Also: Will an Anti-COVID Drug Soon Be Available In Your Neighborhood Pharmacy?

Old HIV Drug

SARS-CoV-2 protease is a key enzyme in the replication of the virus that allows it to spread in the body. Pfizer has developed a molecule, Paxlovid, that can specifically inhibit this enzyme, according to a Pfizer press release.

To evaluate its efficacy, a randomized, double-blind, placebo-controlled Phase 2/3 trial has been launched in July 2021. Given the spectacular results that the drug showed, it was decided to stop the trial ahead of schedule. The clinical trial included 1,219 patients, all of whom were Covid-19 positive, not hospitalized, and with at least one risk factor for developing a severe form of the disease. The treatment is taken orally every 12 hours for 5 days.

Ritonavir

Ritonavir

Treatment of the most vulnerable should be started as soon as possible.

Read Also: COVID-19 Breakthrough: An Inhaled Drug May Reduce the Risk of Complications by 79%

If taken within 3 days of symptom onset, paxlovid reduces the risk of hospitalization and death by 89%. On day 28, the hospitalization rate was 0.8% and the number of patients who died was zero in the treated group, compared to 7% hospitalizations and 7 deaths in the control group.

When taken within 5 days of symptom onset, the results remained significant: 1% of patients hospitalized and no deaths in the treatment group, compared to 6.7% of patients hospitalized and 10 deaths in the control group. There were no more adverse events in the treated group than in the control group.

In short, this new drug could eliminate 9 out of 10 hospital admissions! Pfizer plans to submit an application for Emergency Use Authorization (EUA) to the FDA as soon as possible.

Read Also: Natural COVID-19 Infection Protects Better against the Delta Variant than the Pfizer Vaccine Israeli Study Shows

References

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% In Interim Analysis of Phase 2/3 Epic-HR Study

Articles you may like:

Hearing Loss: MIT Study Shows That COVID-19 Also Attacks Our Ears

Vaccinated People Can Still Contract and Transmit the Delta Variant According to Imperial College Study

Finnish Scientists Produce Lab-Grown Coffee That Tastes Like the Real Thing

What the Rest of the World Can Learn from the Chinese Response to the Pandemic

7 Diseases That Are Transmitted through Tick Bites That You Should Be Aware Of

Burnout Latest Facts: Causes, Risk Factors, Symptoms, Treatment and How to Protect Yourself at Work?

HGH Dosages Currently Being Used for Anti Aging, Weight Loss, and Bodybuilding

Health Insurance: Why It Is Important to Be Insured All the Time

How to Grow Taller

Chronic Pain Can Lead To Anxiety and Depression According to NeuRA Study

Giving Employees the Possibility to Take a 30 Minute Nap Improves Productivity

Global Food Security: Climate Change Is Likely to Cause More Plant Diseases Which Will Affect Crop Yield

HGH Benefits: A list of What to Expect From Using Human Growth Hormone (Somatropin)

Vaccination rates below 90% Could Paradoxically Promote the Emergence of Resistant Variants

Nightmare Scenario: Could the Current Poorly Implemented Vaccination Campaign Lead to More Deadly SARS-CoV-2 Strains

Possible Causes of the Sudden Fall In COVID-19 Infections in the UK and Europe

Moderna and Pfizer’s mRNA Vaccines Do Not Make Straight Men Gay

Gilmore Health

Coronavirus: The Real and False Side Effects of COVID-19 Vaccines

Sponsored:

Genf20 Plus Reviews

Growth Factor Plus Reviews

FEEDBACK:

Conversation

Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.